Friday 6 November 2026 Export TCRT’s income statement to Excel — free account

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024.

Revenue: +200.0%
EPS: +34.9%
Free cash flow: +57.2%

Quarter to June 2026, against a year earlier

1.80 0.04 −2.17%

Follow TCRT

Alert me

Market cap: $7.6M
P/E: 0.0×
Fwd P/E: −2.1×
Dividend yield: —
F-score: 2/9
Altman Z: −436.02
Beneish M: −4.88
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 7.60

Revenue ttm 0.01

Net income ttm (4.01)

Free cash flow ttm (2.73)

Net debt Q (0.12)

Valuation

P/E 0.00

Forward P/E (2.13)

Price / sales 312.69

Forward P/S Powerpack

Price / FCF 0.00

Price / book 6.71

Financial health

Current ratio Q 0.77

Debt / equity Q 0.00

Interest coverage Q (7.47)

Growth

Revenue growth Q +200.00%

Operating income growth Q +8.37%

EPS, this year +11.76%

EPS, next year A +73.33%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 80.83%

10-year low 10-year high

P/B against its own 10 years 74.61%

10-year low 10-year high

EV/Sales against its own 10 years 80.43%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	1	1	0
Receivables	0	0	0	—
Inventory	—	—	—	—
Other	—	—	—	—
	8	3	2	1

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	(49.08%)	(88.04%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(30.95%)	(55.54%)	(61.78%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY23 Estimate −4.50 Actual −6.00

−14.84 −11.92 −9.00 −6.07 −3.15

Q4 FY22 Beat +7.49

Q1 FY23 Met 0.00

Q2 FY23 Met 0.00

Q3 FY23 Miss −1.50

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY22	−13.49	−6.00	Beat by 7.49
Q1 FY23	−6.00	−6.00	Met by 0.00
Q2 FY23	−6.00	−6.00	Met by 0.00
Q3 FY23	−4.50	−6.00	Miss by 1.50

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.59)	(0.41)	—	—	—
’25	(0.67)	(0.63)	(0.55)	(0.38)	(2.20)
’24	(1.10)	(0.71)	(0.70)	(0.46)	(2.92)
’23	(6.00)	(6.00)	(5.30)	(4.89)	(22.00)
’22	(7.50)	(7.50)	(6.00)	(6.00)	(25.49)
’21	(14.99)	(16.49)	(16.49)	(7.50)	(55.47)
’20	(13.49)	(13.49)	(14.99)	(16.49)	(56.97)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	—	0	0
’24	0	0	—	0	0
’23	—	0	—	0	0
’22	—	—	3	0	3
’21	—	—	0	—	0
’18	0	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(2)	(2)	(1)	(1)	(5)
’23	(9)	(7)	(6)	(7)	(30)
’22	(8)	(8)	(6)	(7)	(29)
’21	(15)	(21)	(10)	(15)	(61)
’20	(10)	(14)	(16)	(17)	(57)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(2)	(2)	(1)	(1)	(5)
’23	(9)	(7)	(6)	(6)	(29)
’22	(8)	(8)	(6)	(7)	(29)
’21	(16)	(23)	(10)	(15)	(65)
’20	(10)	(17)	(18)	(21)	(67)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	7	6	0	—	—	0	3	0	0	0	0		(55.2%)	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Alaunos Therapeutics, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(165)	(54)	(53)	(118)	(80)	(79)	(38)	(35)	(5)	(4)	(4)		(33.5%)
	EBT margin, %	(2,409.23)	(850.26)	(36,381.51)	0.00	0.00	(19,786.68)	(1,291.24)	(702,800.00)	(46,790.00)	(83,520.00)	0.00		(81,110.8) pt
	Net income	(165)	(54)	(53)	(118)	(80)	(79)	(38)	(35)	(5)	(4)	(4)		(33.5%)
Per share, $
Per share, $	Revenue	7.89	6.99	0.15	0.00	0.00	0.28	2.02	0.00	0.01	0.00	0.00		(59.0%)
	Earnings	(197.90)	(79.46)	(55.49)	(104.95)	(56.97)	(55.47)	(25.49)	(22.00)	(2.92)	(2.20)	(1.93)		(39.3%)
	Cash flow	(67.06)	(59.85)	(51.67)	(36.47)	(40.77)	(42.98)	(20.19)	(18.84)	(3.10)	(1.47)	(1.12)		(34.6%)
	Capex	(0.63)	(0.81)	(0.48)	(0.25)	(6.99)	(2.32)	(0.13)	0.84	0.00	(0.05)	0.00		(24.5%)
	Free cash flow	(67.70)	(60.66)	(52.15)	(36.72)	(47.77)	(45.31)	(20.33)	(18.00)	(3.10)	(1.52)	(1.12)		(34.4%)
	Book value	(88.88)	(105.98)	89.39	84.82	88.67	40.60	26.64	3.94	1.29	1.11	0.27		n/m
	Shares, m	1	1	1	1	1	1	1	2	2	2	2		+9.4%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	—	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	104.00	95.21	54.37	—	—	62.53	39.26	6.97	278.04	449.52	312.69		136.2
	P/B	0.00	0.00	3.14	—	—	4.03	3.53	3.23	1.48	2.92	6.71		2.3
	EV/Sales	92.19	84.11	41.87	—	—	48.64	30.09	10.18	1,584.32	1,454.88	1,408.11		418.3
	EV/FCF	(10.74)	(9.70)	(4.14)	—	—	(2.81)	(3.54)	(1.03)	(4.81)	(13.92)	(14.92)		(6.3)
Cash, $m
Cash, $m	Operating cash flow	(58)	(55)	(49)	(41)	(57)	(61)	(29)	(30)	(5)	(3)	(3)		(28.4%)
	Capex	(1)	(1)	0	0	(10)	(3)	0	1	—	0	1		(17.5%)
	Free cash flow	(59)	(55)	(50)	(41)	(67)	(65)	(29)	(29)	(5)	(3)	(3)		(28.3%)
Balance, $m
Balance, $m	Working capital	89	70	75	93	112	63	30	6	2	1	0		(38.2%)
	Net debt	(81)	(71)	(62)	(77)	(110)	(52)	(36)	(6)	(1)	(1)	0		(36.4%)
	Shareholders’ equity	(77)	(97)	86	95	124	58	39	6	2	2	1		n/m
Returns, %
Returns, %	ROA	(132.59)	(69.13)	136.80	(115.39)	(62.61)	(65.30)	(47.22)	(96.01)	(84.93)	(145.99)	(128.30)		(13.4) pt
	ROIC	0.00	0.00	(141.35)	(205.22)	(365.89)	(791.83)	(944.09)	(8,741.58)	(309.41)	(343.83)	(480.35)		(343.8) pt
	ROE	(3,423.41)	84.16	(2,441.67)	(130.47)	(73.04)	(86.52)	(78.11)	(156.66)	(111.80)	(198.10)	(185.95)		+3,225.3 pt
People
People	Employees	36	46	48	73	106	41	34	1	1	1	—		(32.8%)
	Revenue/emp, $m	0.19	0.14	0.00	0.00	0.00	0.01	0.09	0.01	0.01	0.01	—		(33.3%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LTRN Lantern Pharma Inc.	$7.9M	— (loss-making)	—	—	n/m	+25.31% (above 0%: growing)	0.00%	0.00%	Compare
TOVX Theriva Biologics, Inc.	$7.7M	— (loss-making)	—	+33.08% (above 0%: growing)	n/m	+34.69% (above 0%: growing)	100.00%	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$7.6M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%
TPST Tempest Therapeutics, Inc.	$7.5M	— (loss-making)	—	−71.57% (below 0%: shrinking)	n/m	+67.04% (above 0%: growing)	0.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$7.5M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.5M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)	Compare
VTGN VistaGen Therapeutics, Inc.	$7.3M	— (loss-making)	— (loss-making)	+504.92% (above 0%: growing)	n/m	+22.23% (above 0%: growing)	100.00%	(904.34%)	Compare
SNGX Soligenix Inc.	$7.3M	— (loss-making)	— (loss-making)	−98.89% (below 0%: shrinking)	n/m	+37.83% (above 0%: growing)	0.00%	0.00%	Compare
XTLB XTL Biopharmaceuticals Ltd.	$7.3M	— (loss-making)	—	−39.32% (below 0%: shrinking)	0.00%	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$7.5M	—	—	−39.49%	—	+36.26%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 21 May 2025

Ownership

Directors and executive officers, together less than 1%

Robert W. Postma 13.11%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Alaunos Therapeutics, Inc. (TCRT) Latest News

13 Oct

Impact 4 · 4:35 PM · biopharmadive.com

Another Paragon spinout goes public through reverse merger

Impact 4 · 1:50 PM · MT Newswires

Top Midday Gainers

Impact 4 · 10:31 AM · GlobeNewswire

Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

Impact 4 · 7:00 AM · PR Newswire

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

18 Sep

Impact 3 · 9:00 AM

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

26 May

Impact 3 · 2:05 PM · Stocktwits

Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers

18 May

Impact 3 · 8:00 AM · GlobeNewswire

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

2 Mar

Impact 4 · 6:30 AM · GlobeNewswire

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

14 Nov

Impact 4 · 7:30 AM · GlobeNewswire

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Impact 3 · 4:31 PM · Associated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press Finance

Ziopharm: Q3 Earnings Snapshot

14 Aug

Impact 4 · 4:05 PM · GlobeNewswire

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Impact 3 · 6:56 PM

Ziopharm: Q2 Earnings Snapshot

23 Jun

Impact 3 · 8:00 AM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

18 Jun

Impact 4 · 9:52 AM

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

14 May

Impact 4 · 8:00 AM · GlobeNewswire

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

4 Apr

Impact 3 · 1:04 PM · Simply Wall St.

Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch

11 Oct

Impact 4 · 8:57 AM · TipRanks

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

29 Jun

Impact 4 · 7:00 AM · GlobeNewswire

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

25 May

Impact 4 · 5:00 PM · GlobeNewswire

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

10 May

Impact 4 · 7:00 AM · GlobeNewswire

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

Alaunos Therapeutics, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Alaunos Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 21 May 2025

Ownership

Alaunos Therapeutics, Inc. (TCRT) Latest News

13 Oct

18 Sep

26 May

18 May

2 Mar

14 Nov

14 Aug

23 Jun

18 Jun

14 May

4 Apr

11 Oct

29 Jun

25 May

10 May

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Alaunos Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 21 May 2025

Ownership

Alaunos Therapeutics, Inc. (TCRT) Latest News

13 Oct

18 Sep

26 May

18 May

2 Mar

14 Nov

14 Aug

23 Jun

18 Jun

14 May

4 Apr

11 Oct

29 Jun

25 May

10 May

Stockrow Weekly